SMT202300250T1 - Trattamento della malattia di alzheimer in una particolare popolazione di pazienti - Google Patents

Trattamento della malattia di alzheimer in una particolare popolazione di pazienti

Info

Publication number
SMT202300250T1
SMT202300250T1 SM20230250T SMT202300250T SMT202300250T1 SM T202300250 T1 SMT202300250 T1 SM T202300250T1 SM 20230250 T SM20230250 T SM 20230250T SM T202300250 T SMT202300250 T SM T202300250T SM T202300250 T1 SMT202300250 T1 SM T202300250T1
Authority
SM
San Marino
Prior art keywords
alzheimer
disease
treatment
particular patient
patient population
Prior art date
Application number
SM20230250T
Other languages
English (en)
Italian (it)
Inventor
Susan Abushakra
Aidan Power
Martin Tolar
John Hey
Jeremy Yu
Petr Kocis
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202300250(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of SMT202300250T1 publication Critical patent/SMT202300250T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM20230250T 2015-09-10 2016-09-09 Trattamento della malattia di alzheimer in una particolare popolazione di pazienti SMT202300250T1 (it)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
EP16845181.3A EP3347002B1 (en) 2015-09-10 2016-09-09 Treatment of alzheimer's disease in a particular patient population
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (1)

Publication Number Publication Date
SMT202300250T1 true SMT202300250T1 (it) 2023-09-06

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20230250T SMT202300250T1 (it) 2015-09-10 2016-09-09 Trattamento della malattia di alzheimer in una particolare popolazione di pazienti

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102547164B1 (enExample)
CN (3) CN116712422A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN108623501B (zh) 2017-03-21 2022-04-19 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN112867485A (zh) * 2018-08-01 2021-05-28 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
JP7466520B2 (ja) * 2018-08-01 2024-04-12 アルツェオン・インコーポレーテッド 神経変性障害を治療するためのスルホプロパン酸誘導体
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
WO2020257159A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20240116529A (ko) * 2021-12-09 2024-07-29 알제온, 인크. 알츠하이머병 치료에 사용하기 위한 alz-801
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE625212T1 (de) 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
ES2967330T3 (es) 2006-10-12 2024-04-29 Bellus Health Inc Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
WO2012024616A1 (en) * 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
EP3718563A1 (en) * 2014-02-08 2020-10-07 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Also Published As

Publication number Publication date
KR20220042480A (ko) 2022-04-05
FI3347002T3 (fi) 2023-08-10
US20220096406A1 (en) 2022-03-31
AU2016319107B2 (en) 2021-02-25
KR102547164B1 (ko) 2023-06-22
US11191742B2 (en) 2021-12-07
CN116712423A (zh) 2023-09-08
AU2016319107A1 (en) 2018-03-22
CN108289870A (zh) 2018-07-17
EP3347002A4 (en) 2019-04-24
KR20180051561A (ko) 2018-05-16
KR102412997B1 (ko) 2022-06-23
JP7128536B2 (ja) 2022-08-31
JP6789579B2 (ja) 2020-11-25
CA2997376C (en) 2024-05-14
WO2017044840A1 (en) 2017-03-16
JP2018526407A (ja) 2018-09-13
SI3347002T1 (sl) 2023-12-29
EP3347002B1 (en) 2023-06-07
PL3347002T3 (pl) 2023-11-13
LT3347002T (lt) 2023-09-11
EP3347002A1 (en) 2018-07-18
CN116712422A (zh) 2023-09-08
RS64481B1 (sr) 2023-09-29
HUE062511T2 (hu) 2023-11-28
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
JP2022145949A (ja) 2022-10-04
HK1257874A1 (en) 2019-11-01
EP4275750A3 (en) 2024-01-17
MD3347002T2 (ro) 2023-10-31
DK3347002T3 (da) 2023-08-14
HRP20230809T1 (hr) 2023-10-27
ES2952727T3 (es) 2023-11-03
MX2022003128A (es) 2022-08-02
MX2018003023A (es) 2018-06-06
MX392677B (es) 2025-03-24
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
PT3347002T (pt) 2023-07-27
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
LT3347002T (lt) Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje
IL247085A0 (en) Methods for treating Alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
IL263188B (en) Treatment for Parkinson's disease
PL3326637T3 (pl) Zastosowanie ekstraktu ze skórki mangostanu w preparatach leczniczych do leczenia chorób skóry
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
HUE056265T2 (hu) Igmezin Alzheimer-kór kezelésében történõ alkalmazásra
EP3137097C0 (en) TREATMENT AND PREVENTION OF ALZHEIMER
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
PL3137093T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL263837A (en) Treatment of ocular disease
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
GB201511453D0 (en) Treatment of alzheimer's disease
AU2017902309A0 (en) Treatment of alzheimer's disease
AU2017902307A0 (en) Treatment of alzheimer's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201610938D0 (en) Treatment of ocular disease